oalib

Publish in OALib Journal

ISSN: 2333-9721

APC: Only $99

Submit

Any time

2019 ( 600 )

2018 ( 1032 )

2017 ( 979 )

2016 ( 1455 )

Custom range...

Search Results: 1 - 10 of 586272 matches for " N.A. Dmitrieva "
All listed articles are free for downloading (OA Articles)
Page 1 /586272
Display every page Item
Acetylsalicylic acid in low doses for secondary prevention of cardio-vascular complications
N.A. Dmitrieva,Tolpygina S.N.
Rational Pharmacotherapy in Cardiology , 2009,
Abstract: Data of evidence based medicine which confirm efficacy of acetylsalicylic acid (ACA) in cardiologic practice are presented. The special attention is given to generic drugs of ACA. Their application has increased essentially recently. Some of generics are comparable with original drugs on clinical efficacy but have economic advantages.
Peculiarities of arterial hypertension diagnosis and secondary prevention according to physicians interviewing
N.S. Oganisyan,N.A. Dmitrieva,A.M. Kochetkov,S.Y. Martsevich
Rational Pharmacotherapy in Cardiology , 2006,
Abstract: Aim. To reveal peculiarities of arterial hypertension (AH) diagnosis and therapy and their matching with international and national guidelines on AH.Material and Methods. An interview among Moscow physicians dealing with hypertensive patients was conducted in April-June 2005. Interview was taken with specially worked out forms containing 15 questions about hypertensive patient management. 102 physicians took part in interviewing, among them 65 internists and 37 cardiologists. Among interviewed physicians 56 ones were from outpatient clinics, 19 — from diagnostic centers, 14 — from hospitals, 5 — from commercial medical centers, 4 — from research center and 3 physicians had private practice.Results. 80,4% of interviewed physicians correctly determined the main goals of AH therapy. 16% of doctors did not indicate blood pressure level below 140/90 mm Hg as target level of secondary prevention. Mainly antihypertensive therapy was presented by four classes of medicines, their shares were as follow: ACE inhibitors — 35%, beta-blockers — 28%, diuretics — 26% and calcium antagonists — 10%. Other classes of antihypertensive medicines (antagonists of angiotensin-II receptors, central acting medicines) made about 1% of share. When choosing original medicine among several suggested trade marks, only 22% of doctors defined the medicine correctly. Original medicines made only 29,4% prescriptions in real medical practice.Conclusion. Real practice of AH diagnosis and therapy considerably differs from international and national guidelines on AH. It is possibly related with lack of appropriate knowledge among physicians as well as problems in public health service.
The state of arterial hypertension diagnostics and treatment, according to the results of the poll among physicians of Volgograd and Volgograd region.
S.Y. Martsevich,N.S. Oganisyan,N.A. Dmitrieva,A.V. Klimakov
Rational Pharmacotherapy in Cardiology , 2005,
Abstract: Aim. Assessment and quality of diagnostics of treatment of patients with arterial hypertension (AH) and their conformity with international and national recommendations on AH.Material and methods. The poll among physicians of Volgograd and Volgograd region, who took part in the regional conference, devoted to the problems of AH, was carried out in April 2004. The questionnaire included 13 questions about peculiarities of AH patients’ management 128 physicians took part in the poll, from them 90 thetapeutists (general physicians), 24 cardiologists, and 14 physicians of different therapeutic specializations.Results. Variability of conceptions of physicians on some principals of diagnostics and treatment of AH patients is revealed. Insufficient knowledge of criteria for division patients according to the risk category of cardiovascular complications. The same is observed for definition of AH grade according to the blood pressure level, and of the main approaches AH patients treatment. From all the questioned physicians only 25.2% correctly evaluated the risk level of cardiovascular diseases, 21% of physicians wrongly assessed the AH grade according to the blood pressure Level.Conclusion. Results, show that real practice of diagnostics and treatment of AH significantly deviates from international and national recommendations on AH.
Influence of mildronate on efficiency of antianginal therapy in patients with stable burden angina
N.P. Kutishenko,N.A. Dmitrieva,Y.V. Lukina,M.P. Kozireva
Rational Pharmacotherapy in Cardiology , 2005,
Abstract: Aim. To study influence of mildronate (M) on treatment efficiency of patients with ischemic heart disease (IHD), receiving standard antianginal therapy (AAT)Materials and methods. Double-blind, randomized, placebo-controlled study was carried out in parallel groups. All patients continued the earlier prescribed AAT without changes. After control period (10-14 days) was over, randomization of patients either to the treatment group (M 500mg twice per day), or to the control group (placebo (Pl) twice per day) was made for 6 weeks therapy. Criterion of treatment efficiency: increase in duration of trial with burden on treadmill (TB), decrease in angina attack frequency (AA) and reduction in nitroglycerin taking (NTT). TB was carried out at the beginning (TB-1), at the end of the control period (TB-2), and at the end of the treatment (TB-3).Results. TB-1 and TB-2 had good reproducibility, their duration didn’t differ. At the end of the treatment additionally with M, growth in duration of TB-3 (p=0,002) was registered, while there was no growth of TB duration with the Pl treatment (p=0,07). During the treatment decrease in AA number both with M (p=0,002), and with Pl (p=0,02) was noted. With M treatment decrease in NTT treatment (p=0.02) was observed, while NTT with Pl didn’t change (p=0,7). Number of side effects, registered with M and Pl, didn’t differ.Conclusion. Mildronate provides additional benefits for patients with IHD with stable burden angina, when they do not reach desired effect with the prescribed AAT.
The choice of the drug amlodipine for the hypertension treatment from the standpoint of economic feasibility
S.Yu. Martsevich,N.A. Dmitrieva,A.D. Deev,Yu.V. Lukina
Rational Pharmacotherapy in Cardiology , 2011,
Abstract: Aim. Тo compare the cost-effectiveness of antihypertensive therapy based on a generic and original drugs of amlodipine in patients with arterial hypertension (HT) degree 1-2 in NORST study.Material and methods. Patients (n=60) with HT degree 1-2 were involved in NORST study. After wash-out period they were randomized to receive generic (Group 1) or original (Group 2) amlodipine in the initial dose of 5 mg daily. In case of insufficient antihypertensive effect dose of amlodipine was increased to 10 mg per day and then successively lisinopril 10 mg daily and hydrochlorothiazide 12.5 mg one time per day were added. The total duration of treatment was 10 weeks (70 days). Achieving target blood pressure (BP) (<140/90 mm Hg) was the criterion of the effectiveness of therapy. Cost-effectiveness analysis of treatments in all patients was performed after individual analysis of the target BP achieving.Results. The target BP level was achieved in 25 (89%) patients of Group 1 and in 27 (96%) patients of Group 2. Total direct costs over 10 weeks amounted to 21 206 rubles in group 1, and 80 073 rubles in group 2. The cost-effectiveness ratio (CER) for group 1 was: CER=21 206/0.89=23 827 rubles. For Group 2, CER=80 073/0.96=83 409 rubles. Costs for achieving target BP in 1 patient of Group 1 were 3,5 times lower than these in group 2.Conclusion. The use of generic amlodipine (Stamlo M) has opportunity to draw in the healing process more hypertensive patients due to reducing the cost of treatment.
The comparative study of efficacy and tolerability of generic and original valsartan as a monotherapy or in combination with hydrochlorothiazide and bisoprolol in patients with arterial hypertension of 1-2 degree and metabolic syndrome
S.Yu. Martsevich,Yu.V. Lukina,N.A. Dmitrieva,O.V. Lerman
Rational Pharmacotherapy in Cardiology , 2012,
Abstract: Aim. To study the efficacy and safety of generic valsartan Valz (Actavis Group, Iceland) in comparison with the original valsartan Diovan (Novartis, Switzerland) in patients with arterial hypertension (HT) of 1-2 degrees and metabolic syndrome.Material and Methods. 30 hypertensive patients (12 men and 18 women) were enrolled in a randomized open-label crossover study. Each patient received generic and original valsartan (80 mg QD) sequentially during 8 weeks. When target blood pressure (BP) level (<130/80 mm Hg) was not reached, a fixed combination of valsartan with hydrochlorothiazide (80/12.5 mg, and then 160/12.5 mg), and bisoprolol 5 mg/daily, if necessary, were used. Treatment efficacy and safety was assessed at visit to doctor every 2 weeks throughout the study. The sequence of drug use was determined by randomization.Results. Systolic BP (SBP) decreased by 27.5 and 27.4 mm Hg from baseline due to generic and original valsartan 8 week treatment, respectively. Diastolic BP (DBP) decreased by 12.8 and 12.9 mm Hg , respectively (p>0.05). Target BP was achieved in 23 patients (77%) in both randomized groups. Serious adverse reaction were not observed during the treatment with both valsartan drugs.Conclusion. The therapeutic equivalence of generic and original valsartan drugs is shown. Therapy based on valsartan (in combination) was safe and effective in 77% of patients with HT of 1-2 degrees and metabolic syndrome.
Comparison of new generic and original ramipril in patients with arterial hypertension and high cardiovascular risk (Full english text)
S.Yu. Martsevich,Yu.V. Lukina,N.A. Dmitrieva,O.V. Lerman
Rational Pharmacotherapy in Cardiology , 2010,
Abstract: Aim. To compare efficacy of ramipril generic HartilR (Egis) to original drug TritaceR in patients with arterial hypertension (HT) of 1-2 degree and high cardiovascular risk, and to evaluate target blood pressure (BP) achievement when taking each drug separately and in combination with the calcium channel blocker amlodipine.Material and methods. A total of 27 patients (14 men, 13 women) with HT of 1-2 degree and high risk due to combination of HT with ischemic heart disease, diabetes or previous stroke were included in an open randomized crossover study. Each patient received generic and original ramipril during 6 weeks by turns. Antihypertensive efficacy (the target BP level <130/80) was evaluated every 2 weeks. In case of treatment inefficiency a dose was doubled and amlodipine (Cardilopin, Egis) was added. After 6 weeks of treatment with the first drug of ramipril the second one was administered.Results. After 6-week Hartil treatment the mean systolic BP (sBP) decreased by 20,0 mm Hg compared to the baseline level, while at Tritace treatment – by 22,2 mm Hg. The mean diastolic BP (dBP) decreased by 10,8 and 8,6 mm Hg respectively (differences between the drugs were insignificant). Twenty patients treated with Hartil and 16 patients treated with Tritace required Cardilopin prescription. The target BP<130/80 was achieved in 10 patients (38,5%) who took Hartil and in 13 patients (50%) treated with the original ramipril (differences between the drugs were insignificant).Conclusion. Therapeutic equivalence of the generic ramipril Hartil and the original drug Tritace was demonstrated. Monotherapy efficacy was low in high-risk patients with HT of 1-2 degree, and combined therapy with two antihypertensive drugs was effective in 40-50% of cases.
A comparative study of efficacy and tolerability of original and generic simvastatin in patients with hyperlipidemia
V.P. Voronina1,S.N. Tolpygina,N.P. Kutishenko,N.A. Dmitrieva
Rational Pharmacotherapy in Cardiology , 2011,
Abstract: Aim. To study efficacy and tolerability of original and generic simvastatin in patients with hyperlipidemia.Material and methods. Patients (6 men and 24 women) aged 38 to 77 years, which needed in lipid-lowering therapy were included into the open, crossover, randomized, comparative study of efficacy and tolerability of original and generic simvastatin. The drug effects on the blood levels of total cholesterol (TC), high density cholesterol (HDC), triglycerides (TG), low density cholesterol (LDC), and tolerability of treatment were evaluated. The treatment duration (with a change of medications) was 12 weeks.Results. The target levels of LDC after 8 weeks of treatment with both generic and original simvastatin (20 mg/day) were achieved in 10 (71.4%) patients in each group. After 8 weeks of therapy with generic and original simvastatin TC decreased from 6.4±0.8 to 4.4±0.6 mmol/l (p<0.001) and from 6.0±0.7 to 4.1±0.7 mmol/l (p<0.001), respectively. LDC levels decreased from 4.4±0.7 to 2.4±0.4 mmol/l (p<0.001) and from 4.2±0.7 to 2.2±0.6 mmol/l (p<0.001), respectively. Both simvastatin medications led to similar changes in blood lipid spectrum and had comparable tolerability.Conclusion. The lipid-lowering effect of the generic simvastatin is comparable to this of original simvastatin. That means generic medication is therapeutically equivalent to original one.
Comparative study of new drug of long acting metoprolol tartrate — Egilok retard and original drug of metoprolol succinate — Betaloc ZOK in patients with mild to moderate arterial hypertension
J.V. Lukina,A.D.Deev,N.A.Dmitrieva,N.Y. Ivanenkova
Rational Pharmacotherapy in Cardiology , 2005,
Abstract: Aim. To study efficiency and safety of new drug of long acting metoprolol tartrate, “Egilok retard” (ER) in patients with mild to moderate arterial hypertension (AH) in comparison with the original drug of metoprolol succinat, “Betaloc ZOK” (BZ), possibility of reaching target blood pressure (BP) level with treatment with each drug.Material and methods. 30 patients (11 men and 19 women) with mild to moderate AH took part in randomized, open, cross over study. Previous antihypertensive treatment had been canceled for all the patients 10-14 days before the study started. Each patient by turns was treated during 6 weeks with ER and BZ 50-100 mg daily. After cancellation of the previous antihypertensive therapy, BZ and ER were prescribed (according to the randomization table) in dose 50 mg daily. Drugs were taken once per day. 29 patients completed therapy with the first drug of randomization, 25 patients — with the second. After 2 weeks efficiency of treatment was assessed by target BP level achievement (< 140/90 mmHg). If efficiency of beta-adrenoblocker (BB) was not sufficient, the dose of the drug was doubled to 100 mg daily, if target level was reached — the dose remained unchanged. Treatment with the settled dose was held within next 4 weeks. After 6-week treatment with the first randomized drug antihypertensive therapy was canceled for 10-14 days depending on the BB dose. At each visit office BP and heart rate were assessed, EKG was registered. Side-effects were registered according to the self-control diary, questionnaire results, examination and EKG data.Results. After 6-week treatment with ER and BZ average level of systolic BP reduced by 15,7 and 15,2 mmHg, of diastolic BP — by 8,0 and 4,5 mmHg, heart rate — by 4,1 and 4,3 beat/min respectively. Differences between antihypertensive and heart rate lowering effect of the studied drugs were not significant. Target BP level with treatment with both drugs was reached in approximately half cases — in 48% of BZ patients, and in 56% of ER patients. Biger number of side effects was registered in BZ treatment (p=0,03). Most side effects were not severe and according to the patient assessment tolerance of both drugs didn’t differ.Conclusion. Results of the study show that in patients with mild to moderate AH 6-week monotherapy with new drug of long acting metoprolol tartrate, ER, does not differ on efficacy and safety from original drug of long acting metoprolol succinate, BZ.
Achievement of target blood pressure level in hypertensive patients with amlodidine: original drug versus generic
S.Yu. Martsevich,N.A. Dmitrieva,A.D.Deev,L.A. Sokolova
Rational Pharmacotherapy in Cardiology , 2009,
Abstract: . To evaluate antihypertensive effects of new generic amlodipine (Stamlo M) in comparison with original amlodipine (Norvasc) in monotherapy and in combination with angiotensin converting enzyme (ACE) inhibitor and diuretic in patients with arterial hypertension (HT) of 1-2 degree.Material and methods. 60 patients with HT of 1-2 degree were included in the open randomized parallel comparative study. Patients were split into 2 groups. Study duration was 10 weeks. Efficacy control, dose correction, addition of ACE inhibitor and diuretic was performed each 2 weeks.Results. The significant antihypertensive effect of monotherapy was observed in both groups already by the 2-4 weeks of therapy. Significant differences between amlodipines in influence on blood pressure (BP) level and heart rate was not found. Monotherapy with generic amlodipine (10 mg OD) provided target BP level more than in half of patients. Achievement of target BP levels was found in 89% and 96% of patients treated with generic and original amlodipine, respectively, when they were combined with lisinopril (10 mg OD) and hydrochlorothiazide (12,5 mg OD). Conclusion. New generic amlodipine (Stamlo M) is an effective and safe antihypertensive drug comparable with original amlodipine in clinical efficacy.
Page 1 /586272
Display every page Item


Home
Copyright © 2008-2017 Open Access Library. All rights reserved.